A novel combinatorial strategy using Seliciclib registered and Belinostat registered for eradication of non-small cell lung cancer via apoptosis induction and BID activation
With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase inhibitor, PXD101 (Belinostat registered ), and CDK inhibitor, CYC202 (Seliciclib registered ), was investigated as an alternative anticancer strat...
Saved in:
Published in | Cancer letters Vol. 381; no. 1; pp. 49 - 57 |
---|---|
Main Authors | , , , , , , , , , , , , , |
Format | Journal Article |
Language | English |
Published |
01.10.2016
|
Online Access | Get full text |
Cover
Loading…
Abstract | With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase inhibitor, PXD101 (Belinostat registered ), and CDK inhibitor, CYC202 (Seliciclib registered ), was investigated as an alternative anticancer strategy. At clinically achievable concentration of CYC202 (15 mu M), combination therapy resulted in significant reduction in cell proliferation (IC50=3.67 plus or minus 0.80 mu M, p<0.05) compared with PXD101 alone (IC50=6.56 plus or minus 0.42 mu M) in p53 wild-type A549 cells. Significant increase in apoptosis that occurred independently of cell cycle arrest was observed after concurrent treatment. This result was corroborated by greater formation of cleaved caspase-8, caspase-3 and PARP. Up-regulation of p53 and truncated BID protein levels was seen while Mcl-1 and XIAP protein levels were down-regulated upon combined treatment. Further analysis of apoptotic pathways revealed that caspase inhibitors, but not p53 silencing, significantly abrogated the cytotoxic enhancement. Moreover, the enhanced efficacy of this combination was additionally confirmed in p53 null H2444 cells, suggesting the potential of this combination for treatment of NSCLC that are not amenable to effects of conventional p53-inducing agents. |
---|---|
AbstractList | With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase inhibitor, PXD101 (Belinostat registered ), and CDK inhibitor, CYC202 (Seliciclib registered ), was investigated as an alternative anticancer strategy. At clinically achievable concentration of CYC202 (15 mu M), combination therapy resulted in significant reduction in cell proliferation (IC50=3.67 plus or minus 0.80 mu M, p<0.05) compared with PXD101 alone (IC50=6.56 plus or minus 0.42 mu M) in p53 wild-type A549 cells. Significant increase in apoptosis that occurred independently of cell cycle arrest was observed after concurrent treatment. This result was corroborated by greater formation of cleaved caspase-8, caspase-3 and PARP. Up-regulation of p53 and truncated BID protein levels was seen while Mcl-1 and XIAP protein levels were down-regulated upon combined treatment. Further analysis of apoptotic pathways revealed that caspase inhibitors, but not p53 silencing, significantly abrogated the cytotoxic enhancement. Moreover, the enhanced efficacy of this combination was additionally confirmed in p53 null H2444 cells, suggesting the potential of this combination for treatment of NSCLC that are not amenable to effects of conventional p53-inducing agents. |
Author | Seah, Jolyn Yu-Xin Yang, Daiwen Kong, Li-Ren Ong, Pei-Shi Lau, Jie-Ying Amelia Chia, Deborah Miao-Hui Thuya, Win-Lwin Sethi, Gautam Wang, Lingzhi Chinnathambi, Arunachalam Wong, Andrea Li-Ann Yong, Wei-Peng Ho, Paul Chi-Lui Goh, Boon-Cher |
Author_xml | – sequence: 1 givenname: Pei-Shi surname: Ong fullname: Ong, Pei-Shi – sequence: 2 givenname: Lingzhi surname: Wang fullname: Wang, Lingzhi – sequence: 3 givenname: Deborah surname: Chia middlename: Miao-Hui fullname: Chia, Deborah Miao-Hui – sequence: 4 givenname: Jolyn surname: Seah middlename: Yu-Xin fullname: Seah, Jolyn Yu-Xin – sequence: 5 givenname: Li-Ren surname: Kong fullname: Kong, Li-Ren – sequence: 6 givenname: Win-Lwin surname: Thuya fullname: Thuya, Win-Lwin – sequence: 7 givenname: Arunachalam surname: Chinnathambi fullname: Chinnathambi, Arunachalam – sequence: 8 givenname: Jie-Ying surname: Lau middlename: Amelia fullname: Lau, Jie-Ying Amelia – sequence: 9 givenname: Andrea surname: Wong middlename: Li-Ann fullname: Wong, Andrea Li-Ann – sequence: 10 givenname: Wei-Peng surname: Yong fullname: Yong, Wei-Peng – sequence: 11 givenname: Daiwen surname: Yang fullname: Yang, Daiwen – sequence: 12 givenname: Paul surname: Ho middlename: Chi-Lui fullname: Ho, Paul Chi-Lui – sequence: 13 givenname: Gautam surname: Sethi fullname: Sethi, Gautam – sequence: 14 givenname: Boon-Cher surname: Goh fullname: Goh, Boon-Cher |
BookMark | eNqVjr1OxEAMhLc4JO6AN6BwSXNh80dCya-ghv7k2ziRT5vdsN5E4qF4R5YTBS2NrdHY38xGrZx3pNRlrrNc5zfXh8ygsxSzIqlMN5kuypVa61JX27It61O1ETloreuqqdfq6w6cX8iC8eOeHUYfGC1IDBhp-IRZ2A3wRpYNG8t7CDSwRArUAboO7pPjvESMf53eB6CAHRuM7B34PqW4rYxoUxKlYeeETU0NBVgYASc_RS8swK6bzfHryH99BExyOYLO1UmPVujid5-pq-en94eX7RT8x0wSdyPLDx8d-Vl2eVs07W2hq7z8x-k3Lh9ujw |
ContentType | Journal Article |
DBID | 7TO H94 |
DOI | 10.1016/j.canlet.2016.07.023 |
DatabaseName | Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitle | Oncogenes and Growth Factors Abstracts AIDS and Cancer Research Abstracts |
DatabaseTitleList | Oncogenes and Growth Factors Abstracts |
DeliveryMethod | fulltext_linktorsrc |
Discipline | Medicine |
EndPage | 57 |
GroupedDBID | --- --K --M .1- .FO .~1 0R~ 1B1 1P~ 1RT 1~. 1~5 29B 3V. 4.4 457 4CK 4G. 5GY 5RE 5VS 6J9 6PF 7-5 71M 7RV 7TO 7X7 8C1 8FE 8FH 8FI 8P~ 9JM AABNK AACTN AAEDT AAEDW AAIKJ AAKOC AALRI AAOAW AAQFI AAWTL AAXKI AAXUO ABBQC ABFNM ABFRF ABGSF ABJNI ABMAC ABMZM ABUDA ACDAQ ACGFO ACGFS ACIUM ACPRK ACRLP ADBBV ADEZE ADFRT ADUVX AEBSH AEFWE AEHWI AEKER AENEX AEVXI AFCTW AFKRA AFKWA AFRAH AFRHN AFTJW AFXIZ AGHFR AGUBO AGYEJ AHHHB AHMBA AIEXJ AIKHN AITUG AJOXV AJRQY AJUYK AKRWK ALMA_UNASSIGNED_HOLDINGS AMFUW AMRAJ ANZVX AXJTR AZQEC BBNVY BENPR BHPHI BKEYQ BKOJK BLXMC BNPGV BPHCQ BVXVI CS3 DU5 EBS EFJIC EJD EO8 EO9 EP2 EP3 F5P FDB FIRID FNPLU FYGXN FYUFA G-Q GBLVA GUQSH H94 HCIFZ IH2 IHE J1W K-O KOM LK8 M1P M29 M2M M2O M41 M7P MO0 N9A O-L O9- OAUVE OC~ OO- OZT P-8 P-9 P2P PC. PQQKQ PROAC Q38 RIG ROL RPZ SCC SDF SDG SDP SEL SES SPCBC SSH SSU SSZ T5K Z5R ~G- |
ID | FETCH-proquest_miscellaneous_18278920413 |
ISSN | 0304-3835 |
IngestDate | Fri Oct 25 11:45:38 EDT 2024 |
IsPeerReviewed | true |
IsScholarly | true |
Issue | 1 |
Language | English |
LinkModel | OpenURL |
MergedId | FETCHMERGED-proquest_miscellaneous_18278920413 |
Notes | ObjectType-Article-1 SourceType-Scholarly Journals-1 content type line 23 ObjectType-Feature-2 |
PQID | 1827892041 |
PQPubID | 23462 |
ParticipantIDs | proquest_miscellaneous_1827892041 |
PublicationCentury | 2000 |
PublicationDate | 20161001 |
PublicationDateYYYYMMDD | 2016-10-01 |
PublicationDate_xml | – month: 10 year: 2016 text: 20161001 day: 01 |
PublicationDecade | 2010 |
PublicationTitle | Cancer letters |
PublicationYear | 2016 |
SSID | ssj0005475 |
Score | 4.463905 |
Snippet | With conventional anticancer agents for non-small cell lung cancer (NSCLC) reaching therapeutic ceiling, the novel combination using histone deacetylase... |
SourceID | proquest |
SourceType | Aggregation Database |
StartPage | 49 |
Title | A novel combinatorial strategy using Seliciclib registered and Belinostat registered for eradication of non-small cell lung cancer via apoptosis induction and BID activation |
URI | https://search.proquest.com/docview/1827892041 |
Volume | 381 |
hasFullText | 1 |
inHoldings | 1 |
isFullTextHit | |
isPrint | |
link | http://utb.summon.serialssolutions.com/2.0.0/link/0/eLvHCXMwnV1LT9tAEF4FKlVcKqCtSnlokDhUshyBs4mdY8pDARGolCClp8iPDTEKNgpxJDjwe3rhPzKzu9k1SqVCL5a1G6_tzKfxzux83zK2F3s1se_H5P2aAgOUhLuBl9TdpB42fK8Rcc6J79y5aLSv-Fm_3q9U_pSqloppVI0f_8or-R-rYhvalViy77CsGRQb8Bzti0e0MB7fZOOWk-UzQQIftxjgUvis6R8k__DgFDIP0BXjNMYr08ihXRhIGEFIfVbnJ3HRc6IUlXukBvgkTHQyT1Z65Jl7f0uL2JTnd8YFEXUJLhNnRqSuu_xumpOyCQb4hd57nMY_PZJaHTNrfauJQBePJZfIzOovld_5JVK3O0ptql81Y9R8_WibD0eqzFc7TKeThrnbLkx_V4QjtTwwfsic34Xb1xrjOsVx0DDFcobaRcs3gdI1mbvtWnCwgE_lhJUGqv6cK_nrhQ-FylncVPHPwnelEj8l4qrIz691uS8uBydX5-eD3nG_t8Q-kOQi7dJQfSoVE3Ep6WwedE7SlJWEi_dY-PDL2UxvlX3SYQi0FKbWWEVk6-xjRxdafGbPLZDQglfQgjm0QEILLLTAAgjQ9GChVe5BaEEJWpAPwUALCFpA0AIFLUBogYEWGGip8U-PwELrC_txctw7bLvz1x2g96Lxwkzkxf0Ao1s_aHr7OJX6ypbxluIbg2GtGUR-hKFHvcZjjucJ6UjyuOl7XhB7G2z3n8N9f8NvNtmKRdsWW55OCrGNU8xptCOt-wJgOYvt |
link.rule.ids | 314,780,784,27924,27925 |
linkProvider | Elsevier |
openUrl | ctx_ver=Z39.88-2004&ctx_enc=info%3Aofi%2Fenc%3AUTF-8&rfr_id=info%3Asid%2Fsummon.serialssolutions.com&rft_val_fmt=info%3Aofi%2Ffmt%3Akev%3Amtx%3Ajournal&rft.genre=article&rft.atitle=A+novel+combinatorial+strategy+using+Seliciclib+registered+and+Belinostat+registered+for+eradication+of+non-small+cell+lung+cancer+via+apoptosis+induction+and+BID+activation&rft.jtitle=Cancer+letters&rft.au=Ong%2C+Pei-Shi&rft.au=Wang%2C+Lingzhi&rft.au=Chia%2C+Deborah+Miao-Hui&rft.au=Seah%2C+Jolyn+Yu-Xin&rft.date=2016-10-01&rft.issn=0304-3835&rft.volume=381&rft.issue=1&rft.spage=49&rft.epage=57&rft_id=info:doi/10.1016%2Fj.canlet.2016.07.023&rft.externalDBID=NO_FULL_TEXT |
thumbnail_l | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/lc.gif&issn=0304-3835&client=summon |
thumbnail_m | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/mc.gif&issn=0304-3835&client=summon |
thumbnail_s | http://covers-cdn.summon.serialssolutions.com/index.aspx?isbn=/sc.gif&issn=0304-3835&client=summon |